spawns
Shares of Altimmune (NASDAQ:ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors on Wall Street a day after issuing notable updates on its lead candidate, pemvidutide.
Betaville, in an "uncooked" alert, around midday trading on Friday, cited a strategic review